Shanghai Pharmaceuticals, Primavera’s $239M Buyout Of Australia’s Vitaco Gets FIRB Approval

A US$239 million deal led by Chinese drugmaker Shanghai Pharmaceuticals Holding Co., Ltd. and private equity firm Primavera Capital to acquire Australian vitamins maker Vitaco Holdings has won approval from Australia’s Foreign Investment Review Board (FIRB), clearing a major roadblock and pushing the deal closer to completion.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in